Related Experiment Video
Updated: Feb 14, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle
Benjamin Goode1, Gourish Mondal1, Michael Hyun1
1Department of Pathology, University of California, San Francisco, CA, 94143, USA.
Abstract:
Chordoid glioma is a rare brain tumor thought to arise from specialized glial cells of the lamina terminalis along the anterior wall of the third ventricle. Despite being histologically low-grade, chordoid gliomas are often associated with poor outcome, as their stereotypic location in the third ventricle makes resection challenging and efficacious adjuvant therapies have not been developed. Here we performed genomic profiling on 13 chordoid gliomas and identified a recurrent D463H missense mutation in PRKCA in all tumors, which localizes in the kinase domain of the encoded protein kinase C alpha (PKCα). Expression of mutant PRKCA in immortalized human astrocytes led to increased phospho-ERK and anchorage-independent growth that could be blocked by MEK inhibition. These studies define PRKCA as a recurrently mutated oncogene in human cancer and identify a potential therapeutic vulnerability in this uncommon brain tumor.
Insights
Chordoid glioma, a rare brain tumor, harbors a specific PRKCA mutation. This discovery identifies a potential therapeutic target for this challenging cancer.
Area of Science:
- Neuro-oncology
- Cancer Genomics
Background:
- Chordoid glioma is a rare brain tumor originating from the lamina terminalis.
- Despite low-grade histology, these tumors have poor outcomes due to location and lack of effective therapies.
Purpose of the Study:
- To investigate the genomic landscape of chordoid glioma.
- To identify potential therapeutic targets for chordoid glioma.
Main Methods:
- Genomic profiling of 13 chordoid glioma samples.
- In vitro functional studies using immortalized human astrocytes expressing mutant PRKCA.
Main Results:
- A recurrent D463H missense mutation in PRKCA was identified in all chordoid gliomas.
- Mutant PRKCA expression increased phospho-ERK and anchorage-independent growth.
- MEK inhibition blocked the effects of mutant PRKCA.
Conclusions:
- PRKCA is a recurrently mutated oncogene in chordoid glioma.
- Targeting MEK presents a potential therapeutic strategy for chordoid glioma.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Viral Mutations
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Anatomy of the Brain: Ventricles

